Design of Viral Vectored Vaccines Targeting Multiple Tumour Neoantigens to Elicit Potent & Effective Anti-tumour Immune Response
Time: 10:00 am
day: Day Two
Details:
- Design of a potent heterologous prime/boost vaccination platform based on viral vectors (non-human Great Ape Adenovirus and MVA) encoding an unprecedented number of tumour neoantigens
- Demonstrating induction of strong and high-quality T cell immune response in vaccinated patients
- Dissecting the contribution of vaccine-induced T cells to clinical responses
